AstraZeneca PLC (AZN)vsGyre Therapeutics Inc. (GYRE)
AZN
AstraZeneca PLC
$188.41
+1.38%
HEALTHCARE · Cap: $284.30B
GYRE
Gyre Therapeutics Inc.
$6.29
-4.30%
HEALTHCARE · Cap: $606.43M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 51536% more annual revenue ($60.44B vs $117.05M). AZN leads profitability with a 17.2% profit margin vs -5.4%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
GYRE
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$188.41
$6.16 discount
Intrinsic value data unavailable for GYRE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Earnings expanding 166.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
Distress zone — elevated risk
2.1% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -6.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : GYRE
The strongest argument for GYRE centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : GYRE
The primary concerns for GYRE are Revenue Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while GYRE is a turnaround play — different risk/reward profiles.
GYRE carries more volatility with a beta of 4.92 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 25/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is an innovative biopharmaceutical company dedicated to advancing therapies for rare and complex diseases through its proprietary platform, which integrates gene therapy and precision medicine. The company boasts a promising pipeline focused on addressing significant unmet medical needs and improving patient outcomes. With a strong commitment to scientific excellence and strategic collaborations, Gyre is strategically positioned for impactful growth in the biopharmaceutical landscape. As it continues to enhance its research and development initiatives, Gyre stands to transform treatment paradigms for patients facing challenging health conditions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?